FindTrial
Sign In

Universal Donor Expanded TGF-beta-imprinted NK Cells

BIOLOGICAL3 trials

Sponsors

Margaret Gatti-Mays, Elvira Umyarova, Kirsten Johnson

Conditions

Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast CarcinomaRecurrent Multiple MyelomaRefractory Multiple MyelomaSkin Basal Cell CarcinomaSkin Nodular Basal Cell CarcinomaSkin Squamous Cell Carcinoma

Early Phase 1

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
RecruitingNCT07144384
Kirsten JohnsonSkin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, Skin Squamous Cell Carcinoma
Start: 2025-10-16End: 2026-12-31Target: 40Updated: 2026-02-13

Phase 1

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
RecruitingNCT06026657
Margaret Gatti-MaysAnatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Start: 2024-04-02End: 2026-12-31Target: 42Updated: 2025-07-08
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Active, not recruitingNCT06203912
Elvira UmyarovaRecurrent Multiple Myeloma, Refractory Multiple Myeloma
Start: 2024-03-05End: 2026-08-31Updated: 2026-03-05

Related Papers

Abstract P3-12-29: Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) cells in Advanced GD2-expressing Breast Cancers (DiG NKs)
Clinical Cancer Research2025-06-13